✨
AI Summary
- Mavacamten received FDA approval for symptomatic obstructive hypertrophic cardiomyopathy in adolescents.
- This approval addresses a significant unmet need in pediatric cardiac care.
- Mavacamten is now the broadest indicated therapy for oHCM.